Critical Comparison: BioCryst Pharmaceuticals (BCRX) vs. Aptevo Therapeutics (APVO)

BioCryst Pharmaceuticals (NASDAQ: BCRX) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings for BioCryst Pharmaceuticals and Aptevo Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCryst Pharmaceuticals 0 3 7 0 2.70
Aptevo Therapeutics 0 0 1 0 3.00

BioCryst Pharmaceuticals currently has a consensus price target of $9.14, suggesting a potential upside of 62.68%. Aptevo Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 36.36%. Given BioCryst Pharmaceuticals’ higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Aptevo Therapeutics.

Valuation and Earnings

This table compares BioCryst Pharmaceuticals and Aptevo Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioCryst Pharmaceuticals $26.35 million 20.99 -$55.14 million ($0.64) -8.78
Aptevo Therapeutics $36.43 million 2.59 -$112.41 million N/A N/A

BioCryst Pharmaceuticals has higher earnings, but lower revenue than Aptevo Therapeutics.

Institutional and Insider Ownership

84.7% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 32.1% of Aptevo Therapeutics shares are held by institutional investors. 5.6% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 15.6% of Aptevo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

BioCryst Pharmaceuticals has a beta of 3.05, meaning that its share price is 205% more volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 3.38, meaning that its share price is 238% more volatile than the S&P 500.

Profitability

This table compares BioCryst Pharmaceuticals and Aptevo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioCryst Pharmaceuticals -172.76% -97.35% -39.80%
Aptevo Therapeutics 5.40% -28.03% -17.46%

Summary

Aptevo Therapeutics beats BioCryst Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company’s investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company’s marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply